Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) (PrEPSteps)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03512418
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : April 28, 2020
Sponsor:
Collaborators:
Brigham and Women's Hospital
Gilead Sciences
Information provided by (Responsible Party):
Peter Chai, Fenway Community Health

Brief Summary:
This study will deploy a novel, personalized, smartphone-based intervention (PrEPSteps) that responds to real time PrEP adherence and non adherence detected through the use of a digital pill. The PrEPSteps intervention will be developed and refined through a series of focus groups. Participants will be screened at a baseline assessment, they will then use the digital pill system for 2 weeks, then undergo randomization to using PrEPSteps + the digital pill, or the digital pill alone to measure PrEP adherence. Participants will undergo 3 monthly study visits where the investigators will assess adherence, conduct pill counts, obtain dried blood spots to confirm adherence, provide substance use disorder counseling and obtain urine drug screens. At the final study visit, the investigators will conduct a semi-structured qualitative interview grounded in the Technology Acceptance Model to understand the user response to PrEPSteps and the digital pill.

Condition or disease Intervention/treatment Phase
HIV Infections Substance Use Disorders Stimulant Use Behavioral: PrEPsteps Device: Digital pill Drug: Truvada Phase 3

Detailed Description:
PrEPSteps is a novel, smartphone-based behavioral intervention that delivers PrEP adherence messages in response to detected PrEP ingestion via an innovative digital pill. PrEPSteps comprises 1) an adaptation of LifeSteps, an evidence-based medication adherence behavioral intervention, with smartphone-delivered booster sessions, 2) messages of contingent reinforcement and corrective feedback, and 3) stimulant use screening, brief assessment, and referral to treatment. In this K23, the investigators will first refine and inform the specification of PrEPSteps with a series of focus groups. The investigators will next test the feasibility, acceptability and potential for an effect of PrEPSteps to boost PrEP adherence in a pilot randomized controlled trial of men who have sex with men (MSM) with stimulant use. Finally, the investigators will conduct qualitative interviews among participants who used PrEPSteps to understand the participant response to living with the intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Pilot randomized controlled trial
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)
Actual Study Start Date : January 24, 2020
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Abuse
Drug Information available for: Truvada

Arm Intervention/treatment
Experimental: PrEPsteps
Participants receive the PrEPsteps intervention that is programmed at the randomization study visit. They will use PrEPsteps and the digital pill to measure Truvada adherence for month 1, then they will revert to digital pill alone with Truvada for month 2 and 3.
Behavioral: PrEPsteps
Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT)

Device: Digital pill
The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.

Drug: Truvada
Participants receive once daily Truvada as PrEP to prevent HIV

Active Comparator: Control
Participants receive digital pills with Truvada to measure PrEP adherence at the randomization study visit and continue with digital pills with Truvada for month 2 and 3.
Device: Digital pill
The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.

Drug: Truvada
Participants receive once daily Truvada as PrEP to prevent HIV




Primary Outcome Measures :
  1. Acceptability of the adherence intervention based on qualitative and quantitive questionnaire [ Time Frame: three month study visit ]
    Acceptability as determined by the mean score of the following questions during study visits (graded on a 1-10 scale): "How satisfied were you with PrEPsteps? How likely are you to recommend PrEPsteps to someone who needs PrEP? How likely are you to recommend PrEPsteps to someone who needs PrEP and uses stimulants?

  2. Feasibility of the adherence intervention qualitative and quantitive questionnaire [ Time Frame: three month study visit ]
    Feasibility of PrEPstesps as determined by the mean number of times intervention was accessed by each study participant during the trial


Secondary Outcome Measures :
  1. Potential of PrEPsteps to improve adherence [ Time Frame: one/two/three month study visits ]
    Comparison of adherence rate in PrEPsteps group versus control

  2. Acceptability of the digital pill [ Time Frame: three month visit ]
    Acceptance of digital pills to monitor PrEP adherence through qualitative interviews


Other Outcome Measures:
  1. Accuracy of digital pill compared to pill counts and dried blood spot for adherence [ Time Frame: one and three month study visits ]
    Accuracy of digital pill in measuring PrEP adherence as compared to dried blood spot testing for tenofovir diphosphate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   cis-gender men who have sex with men (MSM)
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MSM with problematic stimulant use
  • HIV negative
  • On PrEP or initiating PrEP
  • > 18 years old

Exclusion Criteria:

  • Non-english speaker
  • HIV positive
  • Not initiating or does not qualify for PrEP
  • History of bowel surgery, gastric bypass or bowel strictures
  • History of Crohn's disease or ulcerative colitis
  • Unwilling to ingest a digital pill

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03512418


Contacts
Layout table for location contacts
Contact: Peter R Chai, MD, MMS 6177325640 pchai@bwh.harvard.edu
Contact: Samantha Marquez, LCSW 617.927.6465 smarquez@fenwayhealth.org

Locations
Layout table for location information
United States, Massachusetts
Fenway Health Recruiting
Boylston, Massachusetts, United States, 02215
Contact: Peter R Chai, MD, MMS    617-732-5640    pchai@bwh.harvard.edu   
Contact: Samantha Marquez, LCSW    617-927-6465    smarquez@fenwayhealth.org   
Sponsors and Collaborators
Fenway Community Health
Brigham and Women's Hospital
Gilead Sciences
Investigators
Layout table for investigator information
Principal Investigator: Peter R Chai, MD, MMS Brigham and Women's Hospital
Layout table for additonal information
Responsible Party: Peter Chai, Adjunct Faculty, Fenway Community Health
ClinicalTrials.gov Identifier: NCT03512418    
Other Study ID Numbers: 1162312
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: April 28, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Peter Chai, Fenway Community Health:
HIV prevention
Pre-exposure prophylaxis
Digital Pill
Substance use disorder
Stimulant use
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents